Halozyme Therapeutics : Corporate Presentation

Corporate Presentation

August 2021

Forward-Looking Statements

In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2021) and expectations for profitability, revenue (including expectations for future milestones and royalty growth), operating income, cash flow, expenses and earnings-per-share and the Company's plans to continue its share repurchase program and to potentially expand its platform through acquisitions. Forward-looking statements regarding the Company's ENHANZE® drug delivery technology may include the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery or larger volumes of injectable medications through subcutaneous delivery, and lowering the treatment burden for patients and health care system costs. Forward- looking statements regarding the Company's ENHANZE® business may include potential growth driven by our partners' development and commercialization efforts (including anticipated new clinical trial starts, number of products in development and ENHANZE® product approvals and launches), projections for future sales revenue of our collaborators' products, potential new ENHANZE® collaborations, collaborative targets and co-formulation intellectual property. These forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate,"

"anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that

could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues (including royalty and milestone revenue received from our collaboration partners), expenditures and costs, unexpected delays in the execution of the Company's share repurchase program or planned platform expansion, unexpected results or delays in the growth of the Company's ENHANZE® business, obtaining new co-formulation intellectual property, or in the development, regulatory review or commercialization of ENHANZE® products, including any potential delays caused by the current COVID- 19 global pandemic, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.

Non-GAAP Financial Measures:

In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), these materials contain certain non-GAAP financial measures. The Company reports non-GAAP net income and non-GAAP diluted earnings per share and expectations of those

measures in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Reconciliations between GAAP

and non-GAAP financial measures are included in these materials.

Note: This presentation contains product names, trademarks and registered trademarks are property of their respective owners

2

Momentum Building. Long Growth Runway.

Technology for		Significant	Products in
Commercialized	potential
converting IV	development
products using	global sales of
drugs to	using our
our technology	5 approved
subcutaneous	technology
	partner drugs

Only	5	2020: ~$18B	11 in 2020
FDA-approved
recombinant human	~100 countries	2024: ~$22B¹	16 in 2021
hyaluronidase in

partnered products

1. Estimates from Evaluate Ltd. LLC and Bloomberg (December 2020)

Halozyme

royalty revenue projected ~$1B in 2027

~40%

CAGR 2020-2027

3

T H E H A L O Z Y M E S T O R Y

A Repositioned Company. Long Growth Runway.

1	2	3	4	5
Uniquely positioned,	Scalable,	Growing portfolio	Expanding	Strong
momentum	low risk	of marketed	pipeline of future	growth
building	business model	products	products	trajectory

4

W H A T W E D O

Platform Technology Facilitating Subcutaneous Delivery of IV

Delivered Drugs

IV Drug Delivery		ENHANZE® Platform		With Subcutaneous Delivery
				Syringe needle

Long process	Uses proprietary Halozyme fully	Temporarily degrades extracellular
	owned rHuPH20 enzyme	matrix enabling increased fluid flow
		and dispersion of drugs co-formulated
		with ENHANZE®

5